Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.425p +17.89% 2.80p 7,602,258 16:00:03
Bid Price Offer Price High Price Low Price Open Price
2.70p 2.90p 2.975p 2.375p 2.375p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.5 -0.3 -0.1 - 7.89

Feedback (FDBK) Latest News

More Feedback News
Feedback Takeover Rumours

Feedback (FDBK) Share Charts

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart

Intraday Feedback Chart

Intraday Feedback Chart

Feedback (FDBK) Discussions and Chat

Feedback (FDBK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-05-25 16:04:092.95500,00014,750.00O
2018-05-25 16:03:582.94500,00014,700.00O
2018-05-25 15:27:382.9013,931403.72O
2018-05-25 15:24:332.782,00055.50O
2018-05-25 15:21:592.8927,681799.98O
View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

DateSubject
25/5/2018
09:20
Feedback Daily Update: Feedback Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 2.38p.
Feedback Plc has a 4 week average price of 2.25p and a 12 week average price of 1.20p.
The 1 year high share price is 4.13p while the 1 year low share price is currently 1.20p.
There are currently 281,616,584 shares in issue and the average daily traded volume is 1,236,331 shares. The market capitalisation of Feedback Plc is £7,885,264.35.
25/5/2018
11:30
lr2: Agree Brook, if the new guy is willing to pay 3.5p then the share price has plenty of road still to travel.
25/5/2018
11:24
lr2: Well, I hope you enjoy the ride. I've been here awhile now and have no intention of leaving until the share price is significantly higher. I reckon there is so much more to come.
30/4/2018
17:26
tidy 2: SMALL CAP SHARE IDEAS: Heavyweight connections point way forward for medical imaging firm FeedbackGaneshan, who heads the company's medical imaging arm, carried out a study of patients with liver cancer using TexRAD, but impressed by the results Riddell saw wider scale potential.'It quickly dawned on me that this could be a really valuable objective tool for giving an accurate prognosis.'It is in lung cancer that Feedback is now starting to make serious headway.Riddell took over the chair two years ago, but crucial to the recent change of tempo was the award of the European standard CE mark for TexRAD Lung as a diagnosis tool in November.The CE mark means TexRAD Lung can now be sold to hospitals, where it will give numerical support to the work carried out by radiologists.A new chief executive, David Crabb, a software specialist, was recruited in February to spearhead the sales drive for TexRAD.Meanwhile, a tie-up with a company in Poland called Future Processing provides Feedback with the coding know-how to develop a wider product suite.Riddell says the ambition is to move from a company growing modestly to one that will be 'significantly growing'.Feedback's TexRAD texture analysis software can now be sold to hospitals, where it will give numerical support to the work carried out by radiologistsFeedback's TexRAD texture analysis software can now be sold to hospitals, where it will give numerical support to the work carried out by radiologistsSales in the half-year to November were just £229,000 while losses rose to £337,000, so there is plenty to go for.Before the award of the CE mark, the target market was individual research hospitals, now Feedback is going for distribution deals (such as the GEHC one) and major manufacturers such as Philips and Siemens.The 40 per cent jump in the share price on the GE deal news highlights the potential if more deals can be agreed.At 2.75p, Feedback is valued at just £7million and for a company with a CE Mark/European approval for lung cancer imaging it is a modest valuation, especially with the development of new treatments for the disease.As Riddell says: 'That's maybe one of the reasons Simon [Sturge] joined the board.'Feedback also has another product in its stable: an imaging archiving system Cadran that was pioneered by the Royal Papworth Hospital.Papworth has just signed a contract for another two years but Riddell believes there is scope to push Cadran out to a much larger audience.Cadran is not subject to the same regulatory regime as TexRAD, but is a vital part of medical imaging, allowing scans to be easily stored, retrieved and analysed to help diagnosis.Slow burn is probably a fair way to describe the company's progress so far even if the technology is impressive.Undoubtedly given its modest size there's an element of risk attached for investors but Riddell is confident Feedback is starting to move forward.'We have a strong board, good products and there is a huge opportunity to take advantage of our connections in the industry.'In TexRAD and Cadran we have a couple of hidden gems, now we have to burnish them and show them to the world.'
25/4/2018
11:12
lr2: Hi Chopper, always nice to take a profit but I'm hanging on. This is going to be a really big one I reckon and the share price still doesn't reflect the future profit stream to me. I will be here for some time yet. Don't go away too long.
16/4/2018
14:15
lr2: Apparently the daffodils are in 'full bloom' at TexRAD HQ. Share price in 'full bloom' next I hope. https://twitter.com/search?q=%23texrad&src=typed_query
21/3/2018
09:57
lr2: Hi Duc, Nothing new in the podcast but very upbeat nevertheless. The two guys doing all the talking roughly said the following. TexRAD "hugely successful around the globe". Software spots conditions invisible to naked eye. Cadran - medical images archiving - in venture with Future Processing of Poland. Spinoff Stone Checker - royalties will come to Feedback. Investors perplexed by share price performance. Since CE Mark for TexRAD Lung price has declined from 5p. Reason - Trevor Brown selling down (see previous post #1390 for latest detail). Said TB likes new CEO David Crabb but believes board has too many members and none have skin in the game. With business at turning point DC & LM are likely to become significant shareholders in near future. The guys believe Feedback offers significant value and that there isn't a better time to buy in. Hope that helps. LR2.
19/3/2018
18:54
ducatiman: He would be selling at a loss at these levels surely? It is obvious that he just wants to damage the company and its share price or he has an urgent need for cash!
27/2/2018
17:54
lr2: Revenue for the half year was £229k but expectation for 2nd half of year is better so perhaps they will manage £500k+ for full year. Not enough to go without more financing but perhaps not a placing with the share price so weak. Some form of short term bank financing might be considered if share price remains weak and clinical sales come in soon. Whilst a placing is always likely it is not the only option. Probably won't have long to wait to find out the answer as to which way they will go.
20/12/2017
12:58
lr2: What's likely happening here is a petulant old man with a very large holding is pished off with the board of directors now he is no longer a part of it. To hurt the company he used to be an integral part of, he has decided to sell vast numbers of his shares into the market rather than arrange an orderly market disposal, The result - a forcing down of the share price from 3.75p when he started selling to today's opening 1.6p. Even though he is losing vast amounts of money on his remaining holding he views that as worthwhile to his cause. If anyone has an alternative viewpoint on the man's sales then I'd be happy to hear it espoused here.
20/12/2017
11:58
lr2: If TB continues at his current rate of selling 7 million shares a month, he will be done by mid April. What puzzles me is the effect his sales have had on his remaining holding and why he is apparently happy to let it continue. When he first started selling around 6 months back the share price was 3.75p - 4p. It is now 1.6p - 1.62p. In effect TB has reduced the value of his remaining 30.9 million shares by 2.15p a share thus lowering the value of the remaining shares by almost £665k. Why he persists in this self destructive behaviour one can only surmise for he could have arranged an orderly market disposal had he wished but he chose not to do so. I can only conclude his actions are a symbol of his petulance at the current board of directors for some perceived slight.
Feedback share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180525 23:55:54